ARTICLE | Clinical News
Amicus’ Batten disease gene therapy shows preserved speech, motor function
August 2, 2019 12:48 AM UTC
Interim data for Amicus’ most advanced Batten disease gene therapy suggest that the biotech’s recent addition of the modality to its pipeline could be paying off.
On Thursday, Amicus reported interim Phase I/II data showing its AAV-CLN6 gene therapy stabilized motor and speech functions in children with neuronal ceroid lipofuscinosis type 6 (CLN6), a form of Batten disease...
BCIQ Company Profiles
BCIQ Target Profiles